JP2022500470A5 - - Google Patents
Info
- Publication number
- JP2022500470A5 JP2022500470A5 JP2021515030A JP2021515030A JP2022500470A5 JP 2022500470 A5 JP2022500470 A5 JP 2022500470A5 JP 2021515030 A JP2021515030 A JP 2021515030A JP 2021515030 A JP2021515030 A JP 2021515030A JP 2022500470 A5 JP2022500470 A5 JP 2022500470A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- alkyl
- cycloalkyl
- haloalkyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732590P | 2018-09-18 | 2018-09-18 | |
| US62/732,590 | 2018-09-18 | ||
| PCT/US2019/051274 WO2020060915A1 (en) | 2018-09-18 | 2019-09-16 | Cyclopentyl acids as lpa antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500470A JP2022500470A (ja) | 2022-01-04 |
| JP2022500470A5 true JP2022500470A5 (cg-RX-API-DMAC7.html) | 2023-11-08 |
| JP7427658B2 JP7427658B2 (ja) | 2024-02-05 |
Family
ID=68073223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515030A Active JP7427658B2 (ja) | 2018-09-18 | 2019-09-16 | Lpaアンタゴニストとしてのシクロペンチル酸 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12209072B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3852746B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7427658B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102950123B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113473985A (cg-RX-API-DMAC7.html) |
| ES (1) | ES2946657T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020060915A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102800284B1 (ko) * | 2018-09-18 | 2025-04-23 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헵틸 산 |
| JP7412424B2 (ja) * | 2018-09-18 | 2024-01-12 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのオキサビシクロ酸 |
| CN111434655A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| JP2022522534A (ja) | 2019-04-02 | 2022-04-19 | アリゴス セラピューティクス インコーポレイテッド | Prmt5を標的にする化合物 |
| CN114728168B (zh) | 2019-11-15 | 2024-04-09 | 吉利德科学公司 | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 |
| US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| TWI843503B (zh) * | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| IL300525A (en) * | 2020-08-11 | 2023-04-01 | Viva Star Biosciences Ltd | Triazole-pyridinyl-substituted azacyclohexyl acetic acid compounds as LPA receptor antagonists |
| CN117751106A (zh) * | 2021-04-30 | 2024-03-22 | 唯久生物技术(苏州)有限公司 | 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物 |
| AU2022273631B2 (en) * | 2021-05-11 | 2025-04-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| KR20240038004A (ko) * | 2021-07-20 | 2024-03-22 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | Lpa1 소분자 길항제 |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與lpa受體活性相關的病狀的化合物及組合物 |
| US20260226025A1 (en) * | 2023-01-19 | 2026-08-06 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutically acceptable salt and crystal form of triazole compound, and preparation method therefor |
| IL326963A (en) * | 2023-09-08 | 2026-05-01 | Haisco Pharmaceutical Group Co Ltd | LPAR1 antagonist and its use |
| WO2026061483A1 (zh) * | 2024-09-19 | 2026-03-26 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス,インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| TW201120016A (en) | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
| CN107721940A (zh) | 2010-12-07 | 2018-02-23 | 阿米拉制药公司 | 多环lpa1拮抗剂及其使用 |
| WO2012078593A2 (en) | 2010-12-07 | 2012-06-14 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and uses thereof |
| US9527807B2 (en) | 2011-04-05 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| HK1206339A1 (en) | 2012-06-20 | 2016-01-08 | 霍夫曼-拉罗奇有限公司 | N-aryltriazole compounds as lpar antagonists |
| SG11201407220YA (en) | 2012-06-20 | 2014-12-30 | Hoffmann La Roche | N-alkyltriazole compounds as lpar antagonists |
| EP3010908A1 (en) * | 2013-02-20 | 2016-04-27 | E. I. du Pont de Nemours and Company | Fungicidal pyrazoles |
| US8962660B2 (en) | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
| SG11201507459YA (en) | 2013-03-15 | 2015-10-29 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
| JP2017095366A (ja) | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| PE20210655A1 (es) | 2017-12-19 | 2021-03-31 | Bristol Myers Squibb Co | Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa |
| US11319309B2 (en) | 2017-12-19 | 2022-05-03 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as LPA antagonists |
| JP7212047B2 (ja) | 2017-12-19 | 2023-01-24 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール |
| JP7369125B2 (ja) | 2017-12-19 | 2023-10-25 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのイソキサゾールo-架橋カルバモイルシクロヘキシル酸 |
| KR102725744B1 (ko) | 2017-12-19 | 2024-11-01 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 피라졸 아진 |
| ES2962367T3 (es) | 2017-12-19 | 2024-03-18 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA) |
| JP7202383B2 (ja) | 2017-12-19 | 2023-01-11 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのピラゾールo-架橋カルバモイルシクロヘキシル酸 |
| US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| WO2019126087A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
| JP7412424B2 (ja) | 2018-09-18 | 2024-01-12 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのオキサビシクロ酸 |
| KR102800284B1 (ko) | 2018-09-18 | 2025-04-23 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헵틸 산 |
-
2019
- 2019-09-16 ES ES19779299T patent/ES2946657T3/es active Active
- 2019-09-16 EP EP19779299.7A patent/EP3852746B1/en active Active
- 2019-09-16 JP JP2021515030A patent/JP7427658B2/ja active Active
- 2019-09-16 WO PCT/US2019/051274 patent/WO2020060915A1/en not_active Ceased
- 2019-09-16 CN CN201980074355.6A patent/CN113473985A/zh active Pending
- 2019-09-16 US US17/276,176 patent/US12209072B2/en active Active
- 2019-09-16 KR KR1020217011087A patent/KR102950123B1/ko active Active